Drugs / 5-flourouracil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03421353 | Feb 2018 → Jan 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07201766 | Dec 2025 → Feb 2026 overdue | keloid | King Edward Medical University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00255476 Background | Feb 2004 → Jul 2007 | head and neck cancer, squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-flourouracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07201766 ↗ |
| Route | Intravenous | “5-fluorouracil (5FU) by continuous IV infusion” NCT03421353 ↗ |